Canada Pension Plan Investment Board Makes New Investment in Boston Scientific Corporation $BSX

Canada Pension Plan Investment Board purchased a new stake in Boston Scientific Corporation (NYSE:BSX) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 9,262,404 shares of the medical equipment provider’s stock, valued at approximately $395,319,000. Canada Pension Plan Investment Board owned about 0.64% of Boston Scientific at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. BlackRock Inc. bought a new position in shares of Boston Scientific during the second quarter worth about $5,534,781,000. State Street Corp increased its position in Boston Scientific by 1.4% during the 4th quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock valued at $6,278,422,000 after purchasing an additional 920,495 shares during the period. Capital World Investors increased its position in Boston Scientific by 1.9% during the 4th quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock valued at $2,588,953,000 after purchasing an additional 502,627 shares during the period. Norges Bank bought a new position in Boston Scientific during the 4th quarter worth approximately $2,199,395,000. Finally, Morgan Stanley lifted its position in shares of Boston Scientific by 10.8% in the 4th quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock worth $2,189,289,000 after purchasing an additional 2,246,308 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Activity

In other news, CEO Michael F. Mahoney bought 186,240 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was acquired at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the transaction, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. This represents a 13.27% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David C. Habiger purchased 2,100 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The shares were purchased at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the purchase, the director owned 17,160 shares in the company, valued at $816,644.40. This trade represents a 13.94% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have purchased 194,522 shares of company stock worth $9,385,210. Company insiders own 0.34% of the company’s stock.

Boston Scientific Stock Performance

NYSE:BSX opened at $49.86 on Wednesday. The company has a fifty day moving average of $46.44 and a 200-day moving average of $57.14. The firm has a market capitalization of $72.26 billion, a P/E ratio of 20.19, a P/E/G ratio of 1.07 and a beta of 0.56. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a twelve month low of $42.20 and a twelve month high of $109.50.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. The company had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. Boston Scientific’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, sell-side analysts anticipate that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific declared that its Board of Directors has authorized a share repurchase program on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on BSX shares. BTIG Research reduced their price objective on shares of Boston Scientific from $65.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, July 29th. Truist Financial lowered their target price on shares of Boston Scientific from $62.00 to $57.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Barclays dropped their target price on shares of Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a report on Thursday, May 28th. Daiwa Securities Group downgraded Boston Scientific from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Finally, Jefferies Financial Group lowered their price objective on Boston Scientific from $100.00 to $67.00 and set a “buy” rating for the company in a research report on Wednesday, June 24th. Twenty-four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $71.62.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.